GC Genome Corporation (KOSDAQ:340450)

GC Genome Statistics

Total Valuation

GC Genome has a market cap or net worth of KRW 175.02 billion. The enterprise value is 138.92 billion.

Market Cap	175.02B
Enterprise Value	138.92B

Important Dates

The next estimated earnings date is Friday, April 3, 2026.

Earnings Date	Apr 3, 2026
Ex-Dividend Date	n/a

Share Statistics

GC Genome has 23.65 million shares outstanding. The number of shares has increased by 20.01% in one year.

Current Share Class	23.65M
Shares Outstanding	23.65M
Shares Change (YoY)	+20.01%
Shares Change (QoQ)	-0.77%
Owned by Insiders (%)	15.56%
Owned by Institutions (%)	4.04%
Float	13.04M

Valuation Ratios

The trailing PE ratio is 40.00.

PE Ratio	40.00
Forward PE	n/a
PS Ratio	5.55
PB Ratio	2.24
P/TBV Ratio	2.25
P/FCF Ratio	177.58
P/OCF Ratio	134.94
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 29.83, with an EV/FCF ratio of 140.95.

EV / Earnings	34.35
EV / Sales	4.41
EV / EBITDA	29.83
EV / EBIT	77.65
EV / FCF	140.95

Financial Position

The company has a current ratio of 18.59, with a Debt / Equity ratio of 0.05.

Current Ratio	18.59
Quick Ratio	17.67
Debt / Equity	0.05
Debt / EBITDA	0.98
Debt / FCF	4.08
Interest Coverage	6.27

Financial Efficiency

Return on equity (ROE) is 7.26% and return on invested capital (ROIC) is 3.01%.

Return on Equity (ROE)	7.26%
Return on Assets (ROA)	1.23%
Return on Invested Capital (ROIC)	3.01%
Return on Capital Employed (ROCE)	1.51%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.50
Inventory Turnover	10.51

Taxes

In the past 12 months, GC Genome has paid 104.56 million in taxes.

Income Tax	104.56M
Effective Tax Rate	2.52%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	7,800.60
200-Day Moving Average	n/a
Relative Strength Index (RSI)	44.23
Average Volume (20 Days)	278,289

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Genome had revenue of KRW 31.53 billion and earned 4.04 billion in profits. Earnings per share was 185.00.

Revenue	31.53B
Gross Profit	14.63B
Operating Income	1.24B
Pretax Income	4.15B
Net Income	4.04B
EBITDA	4.10B
EBIT	1.24B
Earnings Per Share (EPS)	185.00

Balance Sheet

The company has 40.12 billion in cash and 4.02 billion in debt, with a net cash position of 36.10 billion or 1,526.35 per share.

Cash & Cash Equivalents	40.12B
Total Debt	4.02B
Net Cash	36.10B
Net Cash Per Share	1,526.35
Equity (Book Value)	78.27B
Book Value Per Share	3,335.23
Working Capital	48.23B

Cash Flow

In the last 12 months, operating cash flow was 1.30 billion and capital expenditures -311.39 million, giving a free cash flow of 985.56 million.

Operating Cash Flow	1.30B
Capital Expenditures	-311.39M
Depreciation & Amortization	2.87B
Net Borrowing	-664.11M
Free Cash Flow	985.56M
FCF Per Share	41.67

Margins

Gross margin is 46.39%, with operating and profit margins of 3.92% and 12.83%.

Gross Margin	46.39%
Operating Margin	3.92%
Pretax Margin	13.16%
Profit Margin	12.83%
EBITDA Margin	13.01%
EBIT Margin	3.92%
FCF Margin	3.13%

Dividends & Yields

GC Genome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.01%
Shareholder Yield	-20.01%
Earnings Yield	2.31%
FCF Yield	0.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GC Genome has an Altman Z-Score of 18.66 and a Piotroski F-Score of 5.

Altman Z-Score	18.66
Piotroski F-Score	5